non-cystic fibrosis bronchiectasis market

Jun 19, 2026

Bronchiectasis is a chronic respiratory condition where the bronchial tubes in the lungs become damaged, inflamed, and widened, leading to a buildup of mucus that makes breathing difficult. The condition can develop for various reasons, including infections, genetic disorders, autoimmune conditions, and other facto...

Aug 25, 2025

Insmed’s BRINSUPRI (brensocatib) has achieved a significant regulatory milestone, becoming the first FDA-approved therapy for non-cystic fibrosis bronchiectasis (NCFB) as well as the first approved DPP1 inhibitor. As the only NCFB treatment, this marks not just a scientific breakthrough but also a transformation in...